Matches in Wikidata for { <http://www.wikidata.org/entity/Q66077936> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q66077936 description "clinical trial" @default.
- Q66077936 description "ensayu clínicu" @default.
- Q66077936 description "klinisch onderzoek" @default.
- Q66077936 description "клінічне випробування" @default.
- Q66077936 name "A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMA" @default.
- Q66077936 name "A Study With Upadacitinib" @default.
- Q66077936 type Item @default.
- Q66077936 label "A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMA" @default.
- Q66077936 label "A Study With Upadacitinib" @default.
- Q66077936 prefLabel "A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMA" @default.
- Q66077936 prefLabel "A Study With Upadacitinib" @default.
- Q66077936 P1050 Q66077936-BE0F399F-8522-4594-8722-BEC288EA8712 @default.
- Q66077936 P1132 Q66077936-98F9790F-42AF-43E6-88BD-331F19395D5E @default.
- Q66077936 P1476 Q66077936-705A49EC-A19D-4590-BB7E-2B5BE7515693 @default.
- Q66077936 P17 Q66077936-77282F92-D284-4865-8252-D32B94215C95 @default.
- Q66077936 P2899 Q66077936-B5E7FD05-4B58-43EC-9970-0AB3F0141F2E @default.
- Q66077936 P3098 Q66077936-753BBF30-BE4F-44E2-AB62-DD4193BCEFB0 @default.
- Q66077936 P31 Q66077936-04B3F616-C8DD-4F4F-9070-3624C2933BC1 @default.
- Q66077936 P580 Q66077936-64C901DB-180E-405E-B25F-ABC863D9DB11 @default.
- Q66077936 P582 Q66077936-05DD20B7-DDD7-488F-8E72-B68C3A6E1669 @default.
- Q66077936 P6099 Q66077936-A3E3C379-7689-4E6E-8FF4-57E024B536A2 @default.
- Q66077936 P8363 Q66077936-CA239211-21A6-4500-A04E-35CF791319AA @default.
- Q66077936 P1050 Q170990 @default.
- Q66077936 P1132 "+338" @default.
- Q66077936 P1476 "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)" @default.
- Q66077936 P17 Q155 @default.
- Q66077936 P2899 "+18" @default.
- Q66077936 P3098 "NCT02955212" @default.
- Q66077936 P31 Q30612 @default.
- Q66077936 P580 "2018-01-03T00:00:00Z" @default.
- Q66077936 P582 "2019-07-23T00:00:00Z" @default.
- Q66077936 P6099 Q42824827 @default.
- Q66077936 P8363 Q78089383 @default.